Curetopia captures value by leveraging the power of a decentralized and mission-driven community to tackle the $1 trillion rare disease market, which has long been overlooked by traditional pharmaceutical companies and VC-backed biotech startups. Using a BioDAO framework, Curetopia raises funding via token sales, pooling resources into a treasury that is used to develop real-world scientific assets, including novel drug candidates for rare diseases. This model democratizes drug discovery by aligning incentives across patients, researchers, and funders. By involving patient families as core contributors and rewarding their participation, Curetopia not only accelerates research but also creates shared IP ownership, ensuring that the community directly benefits from the breakthroughs they help achieve.

The value capture flywheel begins with token-based funding that fuels highly capital-efficient R&D on under-addressed diseases. The resulting drugs and IP generate revenues through licensing agreements, partnerships, or direct product sales, with proceeds flowing back into the BioDAO treasury. This reinvestment drives the next wave of drug development and expands the network of patient-driven collaborators, increasing the DAO's impact and financial sustainability. Curetopia’s systematic approach to rare disease treatment, combined with its pioneering application of the BioDAO model, ensures a virtuous cycle where each success amplifies its capacity to tackle the next challenge, making it a transformative force in rare disease drug development.